22:15 , Aug 2, 2018 |  BC Innovations  |  Tools & Techniques

Model firsts

By combining disparate data into coherent mechanistic models, quantitative systems pharmacology is becoming a key tool for picking the right dose for first-in-human trials and other early make-or-break decisions. Advocates see it as part of...
23:26 , Mar 21, 2018 |  BioCentury  |  Finance

Seeking domestic partners

The syndicate behind TCR2 Therapeutics Inc.’s $125 million series B round includes a bevy of Chinese investors who could provide access to development and manufacturing partners in China. 6 Dimensions Capital and Curative Ventures led the...
18:21 , Feb 28, 2018 |  BC Innovations  |  Distillery Techniques

Drug platforms

TECHNOLOGY: Cell therapy CAR T cells engineered to target soluble TGFβ could be useful for treating solid tumors with immunosuppressive microenvironments driven by the cytokine. The CAR T cells are engineered to express a CAR...
01:06 , Jan 6, 2018 |  BioCentury  |  Strategy

CAR dealing

Johnson & Johnson’s deal with Legend Biotech will net the pharma both an anti-BCMA CAR T therapy and a partner to help shape its cell therapy strategy. J&J chose the Chinese company’s LCAR-B38M as its first...
04:17 , Dec 8, 2017 |  BC Week In Review  |  Financial News

Atox Bio raises $30M series F

On Dec. 4, Atox Bio Ltd. (Ness Ziona, Israel) raised $30 million in a series F round led by new investor Arix Bioscience plc (LSE:ARIX), which contributed $8 million. Fellow new investors Adams Street Partners...
02:10 , Dec 8, 2017 |  BC Innovations  |  Targets & Mechanisms

Epiphenomena at ASH

While it’s no surprise that cell therapy research is dominant in hematology, the emergence of epigenetics as an equally large focus at this year’s ASH meeting is more notable, reinforcing the resurgence of a field...
23:28 , Dec 4, 2017 |  BC Extra  |  Company News

Mustang, Harvard partner on CRISPR CAR T therapies

Mustang Bio Inc. (NASDAQ:MBIO) partnered with Harvard University to develop CRISPR-Cas9-enhanced CAR T therapies targeting hematologic and solid tumor cancers. The biotech in-licensed CRISPR-Cas9 gene editing technology from Harvard, as well as technology related to...
19:35 , Dec 4, 2017 |  BC Extra  |  Financial News

Atox Bio raises $30M series F

Atox Bio Ltd. (Ness Ziona, Israel) raised $30 million in a series F round led by new investor Arix Bioscience plc (LSE:ARIX), which contributed $8 million. Fellow new investors Adams Street Partners and Asahi Kasei...
23:52 , Nov 6, 2017 |  BC Extra  |  Preclinical News

Team identifies new target for MM CAR T therapy

In a paper published in Nature Medicine, researchers at Osaka University and colleagues identified activated integrin beta(7) as a new target for a chimeric antigen receptor (CAR) T cell therapy for multiple myeloma, demonstrating that...
21:55 , Oct 26, 2017 |  BC Innovations  |  Translation in Brief

Transient nanotargeting

A team from the Fred Hutchinson Cancer Research Center has designed nanoparticles that introduce mRNA cargo to therapeutic cells in vitro, without requiring special instrumentation or causing the cell depletion or cytotoxicity that limits the...